{"id":9620,"date":"2026-02-28T21:51:45","date_gmt":"2026-02-28T18:51:45","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=9620"},"modified":"2026-02-28T21:51:45","modified_gmt":"2026-02-28T18:51:45","slug":"amiodarone-drug-interactions-in-heart-failure-key-points","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/amiodarone-drug-interactions-in-heart-failure-key-points\/","title":{"rendered":"Amiodarone Drug Interactions in Heart Failure \u2013 Key Points"},"content":{"rendered":"<div>Amiodarone Drug Interactions in Heart Failure \u2013 Key Points<\/div>\n<div><\/div>\n<div>1\ufe0f\u20e3 Negative Chronotropes &amp; Conduction-Slowing Agents<\/div>\n<div><\/div>\n<div>Drugs involved:<\/div>\n<div><span> \u2022 \u03b2-blockers<\/span><\/div>\n<div><span> \u2022 Digoxin<\/span><\/div>\n<div><span> \u2022 Verapamil \/ Diltiazem (non-DHP CCBs)<\/span><\/div>\n<div><span> \u2022 Ivabradine<\/span><\/div>\n<div><span> \u2022 Clonidine<\/span><\/div>\n<div><\/div>\n<div>2\ufe0f\u20e3 Other Antiarrhythmics &amp; QT-Prolonging Agents<\/div>\n<div><\/div>\n<div>Risk of combination:<\/div>\n<div><span> \u2022 QTc prolongation<\/span><\/div>\n<div><span> \u2022 Torsade de pointes (TdP)<\/span><\/div>\n<div><span> \u2022 Proarrhythmia (especially IV amiodarone)<\/span><\/div>\n<div><\/div>\n<div>Clinical guidance:<\/div>\n<div><span> \u2022 Avoid combining with other QT-prolonging drugs unless absolutely necessary<\/span><\/div>\n<div><span> \u2022 Reserve dual therapy for life-threatening ventricular arrhythmias<\/span><\/div>\n<div><span> \u2022 Monitor QTc closely<\/span><\/div>\n<div><\/div>\n<div>3\ufe0f\u20e3 Diuretics &amp; Electrolyte-Disturbing Therapies<\/div>\n<div><\/div>\n<div>Electrolyte abnormalities that increase risk:<\/div>\n<div><span> \u2022 Hypokalemia<\/span><\/div>\n<div><span> \u2022 Hypomagnesemia<\/span><\/div>\n<div><span> \u2022 Hypocalcemia<\/span><\/div>\n<div><\/div>\n<div>Common contributing therapies:<\/div>\n<div><span> \u2022 Loop and thiazide diuretics<\/span><\/div>\n<div><span> \u2022 Laxatives<\/span><\/div>\n<div><span> \u2022 Systemic corticosteroids<\/span><\/div>\n<div><span> \u2022 IV amphotericin B<\/span><\/div>\n<div><span> \u2022 Severe or prolonged diarrhea<\/span><\/div>\n<div><\/div>\n<div>Clinical principle:<\/div>\n<div><span> \u2022 Correct electrolytes before and during amiodarone therapy<\/span><\/div>\n<div><span> \u2022 Monitor K\u207a and Mg\u00b2\u207a regularly<\/span><\/div>\n<div><\/div>\n<div>4\ufe0f\u20e3 Anticoagulation Interaction<\/div>\n<div><\/div>\n<div>Warfarin interaction:<\/div>\n<div><span> \u2022 Amiodarone increases INR<\/span><\/div>\n<div>Clinical action:<\/div>\n<div><span> \u2022 Frequent INR monitoring after initiation<\/span><\/div>\n<div><span> \u2022 Warfarin dose reduction often required<\/span><\/div>\n<div><\/div>\n<div>5\ufe0f\u20e3 Device Therapy (ICD \/ Pacemaker Context)<\/div>\n<div><span> \u2022 May alter pacing thresholds<\/span><\/div>\n<div><span> \u2022 May alter defibrillation thresholds<\/span><\/div>\n<div><\/div>\n<div>Recommendation:<\/div>\n<div><span> \u2022 Reassess device parameters after starting amiodarone<\/span><\/div>\n<div><\/div>\n<div>Summary Teaching Pearl<\/div>\n<div><\/div>\n<div>In heart failure patients, amiodarone interactions primarily involve:<\/div>\n<div><span> \u2022 Bradycardia &amp; conduction delay<\/span><\/div>\n<div><span> \u2022 QT prolongation &amp; TdP risk<\/span><\/div>\n<div><span> \u2022 Electrolyte-mediated proarrhythmia<\/span><\/div>\n<div><span> \u2022 Warfarin potentiation<\/span><\/div>\n<div><span> \u2022 Device threshold changes<\/span><\/div>\n<div><\/div>\n<div>Medscape Reference<\/div>\n<div>Last updated: February 2026<\/div>\n<div><\/div>\n<div><a href=\"http:\/\/reference.medscape.com\/drug\/pacerone-cordarone-amiodarone-342296\">http:\/\/reference.medscape.com\/drug\/pacerone-cordarone-amiodarone-342296<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Amiodarone Drug Interactions in Heart Failure \u2013 Key Points 1\ufe0f\u20e3 Negative Chronotropes &amp; Conduction-Slowing Agents Drugs involved: \u2022 \u03b2-blockers \u2022 Digoxin \u2022 Verapamil \/ Diltiazem (non-DHP CCBs) \u2022 Ivabradine \u2022 Clonidine 2\ufe0f\u20e3 Other Antiarrhythmics &amp; QT-Prolonging Agents Risk of combination: \u2022 QTc prolongation \u2022 Torsade de pointes (TdP) \u2022 Proarrhythmia (especially IV amiodarone) Clinical guidance: [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-9620","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9620","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=9620"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9620\/revisions"}],"predecessor-version":[{"id":9621,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9620\/revisions\/9621"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=9620"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=9620"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=9620"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}